News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
93 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37190)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53929)
2023 (42568)
2024 (38488)
2025 (26980)
Month
January (2883)
February (2030)
March (1769)
April (2200)
May (2664)
June (3162)
July (3087)
August (3801)
September (4260)
October (5136)
November (4629)
December (3503)
Day
1 (92)
2 (55)
3 (1)
4 (4)
5 (65)
6 (116)
7 (86)
8 (101)
9 (46)
10 (4)
11 (5)
12 (90)
13 (97)
14 (81)
15 (116)
16 (43)
17 (1)
18 (12)
19 (98)
20 (90)
21 (83)
22 (111)
23 (47)
26 (66)
27 (70)
28 (93)
29 (55)
30 (39)
31 (2)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
26
27
28
29
30
31
Drug Development
Urovant Sciences Initiates Phase 3 Clinical Program for Vibegron in Patients with Overactive Bladder
Pivotal trial will enroll approximately 1,400 patients for 12-week treatment period.
March 28, 2018
·
3 min read
Business
Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2017 Financial Results
Alpine Immune Sciences, Inc. provided a corporate update and reported financial results for the year ended December 31, 2017.
March 28, 2018
·
6 min read
Drug Development
MiMedx Enrolls First Patient In Its Phase 2B Clinical Trial Of RMAT Designated AmnioFix® Injectable For The Treatment Of Osteoarthritis Of The Knee
Initiation of Phase 2B Study Follows Quickly After FDA Grants RMAT Designation for Knee OA.
March 28, 2018
·
4 min read
Business
Sarah Wilkinson, CEO of NHS Digital, Named U.K. Chief Digital Officer of the Year 2017 by CDO Club
Ms. Wilkinson was presented with the award after her keynote on “Digitising the National Health Service” at the 3rd U.K. CDO Summit in London, England, by CDO Club founder David Mathison.
March 28, 2018
·
4 min read
Business
bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States
bluebird and Celgene will share 50% of U.S. costs and profits
March 28, 2018
·
5 min read
Deals
PTC Therapeutics Announces Pricing of Public Offering of Common Stock
PTC Therapeutics, Inc. announced the pricing of a public offering of 4,000,000 shares of its common stock at a public offering price of $27.04 per share, before underwriting discounts.
March 28, 2018
·
2 min read
Business
Alliar Announces 4Q17 Results
Centro de Imagem Diagnósticos SA announces its results for the fourth quarter of 2017 (4Q17).
March 28, 2018
·
1 min read
Business
Regional Health Properties Postpones Conference Call to Discuss Fourth Quarter and Year End 2017 Financial Results
Regional Health Properties, Inc. announced postponing the release of its financial results for the fourth quarter and full-year period ended December 31, 2017 and its previously announced conference call to discuss such results originally scheduled for March 29, 2018.
March 28, 2018
·
1 min read
Drug Development
Prometic Reports Positive Clinical Data From Ongoing PBI-4050 Study in Alström Syndrome Patients
Clinical benefits in both heart and liver observed in patients treated with PBI-4050 over an average of 52 weeks of treatment.
March 28, 2018
·
7 min read
Toshiba Heavy-Ion Therapy System Awarded by Yonsei University Health System
Toshiba Energy Systems & Solutions Corporation in collaboration as a consortium with DK Medical Solutions is awarded a contract to supply a heavy-ion therapy system to Yonsei University Health System (YUHS), one of the leading providers of medical services in Korea.
March 28, 2018
·
3 min read
Previous
6 of 10
Next